Answers are grounded in this paper and cite their sources.
Experimental study demonstrates that decorin and IL-10 overexpression improves outcomes in pulmonary fibrosis mice, suggesting potential therapeutic strategies.
Background: This study investigated whether the double overexpression of decorin and IL-10 in human bone marrow-derived mesenchymal stem cells [HBMDMSCs DO (DEC/IL-10) ] can protect against bleomycin (BLM)-induced pulmonary fibrosis (PF) in mice. Methods: L2 and NR8383 cells were treated with BLM (0–2.5 μg/mL). In vivo , animals were assigned to four groups: Group 1 – sham control (SC); Group 2 – PF; Group 3 – PF + HBMDMSCs; Group 4 – PF + HBMDMSCs DO (DEC/IL-10) . Results: BLM, at its IC 50 , significantly reduced the viability of L2 and NR8383 cells while increasing early and late apoptosis and TGF-β expression ( P < 0.001). BLM treatment in L2 cells induced oxidative stress (mitochondrial ROS, NOXs/p22 phox ), cell-stress signaling (MAPKs), and epithelial–mesenchymal transition (EMT) biomarkers, which were reversed by decorin, HBMDMSCs, decorin-overexpressing HBMDMSCs, or p22 phox silencing ( P < 0.001). Decorin silencing in L2 and CG1629 cells upregulated EMT and cell-stress markers, effects reversed by decorin treatment, decorin overexpression, or MSC DO (DEC/IL-10) ( P < 0.001). In BLM-induced PF mice, SaO 2 was highest in Group 1, lowest in Group 2, and higher in Group 4 than Group 3, while lung injury, fibrosis, right-ventricular pressure, and inflammatory cells showed the opposite trend ( P < 0.0001). Lung expression of EMT/proliferation (c-Myc, Cyclin D/E, Wnt/β-catenin), oxidative stress (p22 phox , OxyBlot), and fibrosis (TGF-β, p-Smad3) proteins mirrored lung injury scores ( P < 0.0001). Conclusion: HBMDMSCs DO (DEC/IL-10) treatment effectively protected the lungs from BLM-induced PF in rodents.
No takes yet. Share an insight, caveat, or question.
Yue et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: